Hexaminolevulinate-mediated photodynamic purging of leukemia cells from BM. Bone Marrow Transplant 2010 Oct;45(10):1553-61
Date
02/02/2010Pubmed ID
20118993DOI
10.1038/bmt.2009.382Scopus ID
2-s2.0-77957932322 (requires institutional sign-in at Scopus site) 5 CitationsAbstract
Photodynamic therapy (PDT) with porphyrin precursors has been established for tumor treatment. This study aimed at examining applicability of hexaminolevulinate (HAL) for photodynamic purging of leukemic cells from BM grafts and evaluating the clinical relevance of in vitro models. The PDT dose resulting in no colony formation by leukemic cells in vitro, in pure form or in a mixture with BM cells, was insufficient for complete killing of the leukemic cells ex vivo and for the treatment of the leukemia-bearing animals in vivo. The efficacy of HAL-PDT in cell lines in vitro should be verified in clinically relevant in vivo models.
Author List
Čunderlíková B, Vasovič V, Sieber F, Furre T, Nesland JM, Peng QAuthor
Fritz Sieber PhD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Aminolevulinic AcidAnimals
Bone Marrow Cells
Bone Marrow Purging
Bone Marrow Transplantation
Cell Line, Tumor
Cell Survival
Female
Gamma Rays
Granulocytes
Leukemia L1210
Mice
Mice, Inbred DBA
Osmolar Concentration
Photochemotherapy
Photosensitizing Agents
Protoporphyrins
Survival Analysis
Tumor Stem Cell Assay
Whole-Body Irradiation
